Newer strategies for effective evaluation of primary melanoma and treatment of stage III and IV disease (Q33846098)

29 July 2017

1 reference

title

Newer strategies for effective evaluation of primary melanoma and treatment of stage III and IV disease (English)

1 reference

29 July 2017

Walsh P

1

1 reference

29 July 2017

Gibbs P

series ordinal

2

1 reference

29 July 2017

Gonzalez R

series ordinal

3

1 reference

29 July 2017

language of work or name

English

0 references

publication date

1 March 2000

1 reference

Journal of the American Academy of Dermatology

29 July 2017

published in

1 reference

29 July 2017

volume

42

1 reference

29 July 2017

issue

3

1 reference

29 July 2017

page(s)

480-489

1 reference

Clinical and histologic trends of melanoma

29 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2800%2990223-8

7 January 2021

An estimate of the annual direct cost of treating cutaneous melanoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2800%2990223-8

7 January 2021

https://api.crossref.org/works/10.1016%2FS0190-9622%2800%2990223-8

1 reference

7 January 2021

The relationship of embolic homogeneity, number, size and viability to the incidence of experimental metastasis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2800%2990223-8

7 January 2021

Lymphadenectomy in the management of stage I malignant melanoma: a prospective randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2800%2990223-8

7 January 2021

Inefficacy of immediate node dissection in stage 1 melanoma of the limbs

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2800%2990223-8

7 January 2021

Delayed regional lymph node dissection in stage I melanoma of the skin of the lower extremities

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2800%2990223-8

7 January 2021

Stage I melanoma of the limbs. Immediate versus delayed node dissection

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2800%2990223-8

7 January 2021

Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2800%2990223-8

7 January 2021

Technical details of intraoperative lymphatic mapping for early stage melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2800%2990223-8

7 January 2021

The orderly progression of melanoma nodal metastases

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2800%2990223-8

7 January 2021

Role of lymphatic mapping and sentinel node biopsy in the detection of melanoma nodal metastases

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2800%2990223-8

7 January 2021

Minimal-access surgery for staging of malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2800%2990223-8

7 January 2021

Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2800%2990223-8

7 January 2021

Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2800%2990223-8

7 January 2021

Detection of submicroscopic lymph node metastases with polymerase chain reaction in patients with malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2800%2990223-8

7 January 2021

Patterns of relapse in 1001 consecutive patients with melanoma nodal metastases

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2800%2990223-8

7 January 2021

Prognostic factors in patients with regional cervical nodal metastases from cutaneous malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2800%2990223-8

7 January 2021

Neck dissection for cutaneous malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2800%2990223-8

7 January 2021

Modified ilioinguinal node dissection for metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2800%2990223-8

7 January 2021

Prognostic value of size of lymph node metastases in patients with cutaneous melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2800%2990223-8

7 January 2021

A randomized trial of adjuvant chemotherapy and immunotherapy in cutaneous melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2800%2990223-8

7 January 2021

Corynebacterium parvum versus bacille Calmette-Guérin adjuvant immunotherapy of stage II malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2800%2990223-8

7 January 2021

A randomized trial of levamisole versus placebo as adjuvant therapy in malignant melanoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2800%2990223-8

7 January 2021

A randomized trial of levamisole versus placebo as adjuvant therapy in malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2800%2990223-8

7 January 2021

Randomized, surgical adjuvant clinical trial of recombinant interferon alfa-2a in selected patients with malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2800%2990223-8

7 January 2021

Results of adjuvant interferon study in WHO melanoma programme

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2800%2990223-8

7 January 2021

Overview of melanoma vaccines: active specific immunotherapy for melanoma patients

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2800%2990223-8

7 January 2021

A phase III randomized, double-blind multiinstitutional trial of vaccinia melanoma oncolysate-active specific immunotherapy for patients with stage II melanoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2800%2990223-8

7 January 2021

Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2800%2990223-8

7 January 2021

Generation of cytotoxic T-cell responses with synthetic melanoma-associated peptides in vivo: implications for tumor vaccines with melanoma-associated antigens

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2800%2990223-8

7 January 2021

Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2800%2990223-8

7 January 2021

Dendritic cell vaccines for cancer immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2800%2990223-8

7 January 2021

Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2800%2990223-8

7 January 2021

Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2800%2990223-8

7 January 2021

Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2800%2990223-8

7 January 2021

Effect of DETOX as an adjuvant for melanoma vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2800%2990223-8

7 January 2021

Cancer statistics, 1998.

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2800%2990223-8

7 January 2021

A multifactorial analysis of melanoma. IV. Prognostic factors in 200 melanoma patients with distant metastases (stage III)

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2800%2990223-8

7 January 2021

Prognostic factors in patients with metastatic malignant melanoma. A multivariate analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2800%2990223-8

7 January 2021

Surgery as palliative treatment for distant metastases of melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2800%2990223-8

7 January 2021

Surgical treatment of distant metastatic melanoma. Indications and results

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2800%2990223-8

7 January 2021

Surgical versus nonsurgical management of metastatic melanoma of the brain

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2800%2990223-8

7 January 2021

Dimethyl triazeno imidazole carboxamide and combination therapy for melanoma. IV. Late results after complete response to chemotherapy (Central Oncology Group protocols 7130, 7131, and 7131A)

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2800%2990223-8

7 January 2021

The importance of tamoxifen to a cisplatin-containing regimen in the treatment of metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2800%2990223-8

7 January 2021

Interleukin-2 and high-dose cisplatin in patients with metastatic melanoma: a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2800%2990223-8

7 January 2021

Sequential chemoimmunotherapy with cisplatin, interleukin-2, and interferon alfa-2a for metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2800%2990223-8

7 January 2021

A phase II study of dacarbazine and cisplatin in combination with outpatient administered interleukin-2 in metastatic malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2800%2990223-8

7 January 2021

Multiinstitutional phase II trial of intensive combination chemoimmunotherapy for metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2800%2990223-8

7 January 2021

Combination of chemotherapy with interleukin-2 and interferon alfa for the treatment of metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2800%2990223-8

7 January 2021

Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2800%2990223-8

7 January 2021

10.1016/S0190-9622(00)90223-8

Identifiers

DOI

1 reference

29 July 2017

1 reference